Mytos

To solve this, Mytos devices use the same T-flasks used in manual cell culture - so cells won't know the difference - and a closed system, meaning the internal infrastructure never comes into contact with non-sterile air. This is all configurable so it's easy for scientists to make changes to culturing protocols and schedules. Whilst lab automation is not new, especially in big pharma, it is mostly available for large-scale manufacturing of cell products. Lab automation companies, like Opentrons in the US, focus on more general applications such as pipetting.

In early 2023, Mytos' platform went live for Pharma customers, with partners including 5 of the top US multi-billion dollar biotechs. Having already worked with companies such as Orchard Therapeutics and with several investors backing the company, Mytos aims to position itself at the centre of biotech automation.